All In Biotech

Drug Trial Radar · NCT07148960

Does Staphylococcus Aureus Bacteremia Early Dual Therapy Improve Outcomes?

Does Staphylococcus Aureus Bacteremia Early Dual Therapy Improve Outcomes? (SABEDTIO) Clinical Trial

Last checked: Nov 19, 2026Latest source record: Sep 17, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Enrolling by invitationPivotal-lookingRandomized with 300 participants. This is a heuristic, not a regulatory label.

Status

Enrolling by invitation

Enrollment

300

Planned (sponsor's estimate)

Start

Sep 15, 2025

Primary completion

Jul 2027

Study completion Jul 2027

Sponsor

Lead sponsor
West Virginia UniversityAcademic, hospital or other
Sponsor type
Academic, hospital or other
First posted
Aug 29, 2025

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 4
Allocation
Randomized
Model
Parallel
Masking
None
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The goal of this open-label, pragmatic, randomized controlled clinical trial is to learn if patients with Staphylococcus aureus bacteremia (SAB) given the intervention of early dual intravenous (IV) antibiotic therapy will decrease duration of bacteremia (\< 6 days) and improve outcomes compared to single IV antibiotic therapy. The main questions this study aims to answer are: * To decrease SAB duration and improve outcomes by using early dual vs. single agent IV antibiotic therapy * To accelerate practice transformation of earlier IV to oral (PO) antibiotic transition by switching to PO antibiotic therapy once blood cultures are negative at 72 hours Participants will be asked to agree to be randomized (like flipping a coin) to receive two or one IV antibiotic(s). Once the infection has cleared, the treatment will be changed to PO antibiotics. As part of usual care, participants will have weekly lab tests for monitoring while on antibiotics, receive a telephone call to see how the participants are doing, and follow up in person or by telephone or video in Infectious Diseases (ID) Clinic. Participant participation will last 12 weeks after the participant is discharged from the hospital.

Conditions

  • Staphylococcus Aureus Bacteremia

Interventions

  • Early Dual IV Antibiotic Therapy - MRSADrug

    Participant given IV daptomycin plus ceftaroline dosing per standard of care. Oral rifampin may be added for participants with prosthetic material.

  • Early Dual IV Antibiotic Therapy - MSSADrug

    Participant given IV cefazolin plus ertapenem dosing per standard of care. Oral rifampin may be added for participants with prosthetic material.

  • Single Agent IV Antibiotic Therapy - MRSADrug

    Participant given one of the following IV therapies: daptomycin, vancomycin, or ceftaroline. Oral rifampin may be added for participants with prosthetic material.

  • Single Agent IV Antibiotic Therapy - MSSADrug

    Participant given one of the following IV therapies: cefazolin, oxacillin, or nafcillin. Oral rifampin may be added for participants with prosthetic material.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Percentage of participants with prolonged bacteremia (≥ 6 days)Time frame: Up to 12 weeks post hospital discharge
  2. Seeding of a New Site - IncidenceTime frame: Up to 12 weeks post hospital discharge
  3. All-Cause MortalityTime frame: Up to 12 weeks post hospital discharge

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • West Virginia University

    Morgantown, West Virginia

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.